China SXT Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SXTC research report →
Price Chart
About the company
China SXT Pharmaceuticals, Inc. , a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang.
- CEO
- Feng Zhou
- IPO
- 2019
- Employees
- 56
- HQ
- Taizhou, JS, CN
Get TickerSpark's AI analysis on SXTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.94M
- P/E
- -0.43
- PEG
- 0.00
- P/S
- 0.76
- P/B
- 0.07
- EV/EBITDA
- 3.00
- Div Yield
- 0.00%
- Gross Margin
- 44.37%
- Op Margin
- -336.53%
- Net Margin
- -290.71%
- ROE
- -31.02%
- ROIC
- -23.34%
Latest fiscal year · YoY change
- Revenue
- $1.07M-38.4%
- Gross Profit
- $183.28K-50.1%
- Op Income
- $-7,122,933
- Net Income
- $-6,205,085-87.8%
- EPS
- $-9.13-11.6%
- OCF Growth
- -71.3%
- FCF Growth
- -71.1%
- 52W High
- $83760.00
- 52W Low
- $3.10
- 50D MA
- $113.01
- 200D MA
- $4232.01
- Beta
- 1.90
- RSI (14)
- 24
- Avg Volume
- 987.27K
No earnings-call transcripts are available for SXTC yet.
- Free Float
- 82.5%
- Shares Outstanding
- 533.98K
- Float Shares
- 440.62K
of shares held by institutions
5 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 22 | Pan Xiaodong Sean | other | 0 |
| Jul 4, 17 | Zhou Feng Felix | other | 0 |
| Jan 20, 25 | Chee Yong Lip | other | 0 |
| May 22, 21 | Ji Xiaodong | other | 0 |
| May 10, 22 | Liu Tong Tony | other | 0 |
| Jan 20, 25 | Simon Lim Sze Beng | other | 0 |
| Dec 31, 18 | Zheng Jun | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SXTC coverage
Recent articles, reports, and earnings notes.
No research on SXTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SXTC report →China SXT Pharmaceuticals, Inc. Announces Share Consolidation
globenewswire.com · Aug 5
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
globenewswire.com · Jul 24
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
globenewswire.com · Jul 24
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
globenewswire.com · Jul 23
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June
defenseworld.net · Jul 19
Cumberland Pharmaceuticals (NASDAQ:CPIX) & China SXT Pharmaceuticals (NASDAQ:SXTC) Head-To-Head Analysis
defenseworld.net · Apr 6
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
globenewswire.com · Mar 23
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 29.1% in February
defenseworld.net · Mar 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.